Search results
Author(s):
Steven E Nissen
,
Maryam Barkhordarian
Added:
1 year ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is…
View more
Remnant Lipoproteins and ASCVD
Author(s):
Mohanad Gabani
,
Michael D Shapiro
,
Peter P Toth
Added:
1 year ago
Article
Author(s):
Steven E Nissen
Added:
1 month ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,…
View more
Author(s):
Michelle O'Donoghue
Added:
1 year ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview.
OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered…
View more
Author(s):
Steven E Nissen
Added:
5 months ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial…
View more
AHA 24: The KRAKEN Trial
Author(s):
Stephen Nicholls
Added:
5 months ago
Video
Alberico L Catapano
Research Area(s) / Expertise:
Job title: Professor of Pharmacology and Director of the Laboratory of Lipoprotein Metabolism of the Centre for the Study, Prevention and Therapy of Atherosclerosis
Author
Raif Tawakol
Job title: Director
Author
Author(s):
Rishi Rikhi
,
Michael D Shapiro
Added:
1 year ago